RU2015142279A - Новые соединения и композиции для нацеливания на злокачественные стволовые клетки - Google Patents
Новые соединения и композиции для нацеливания на злокачественные стволовые клетки Download PDFInfo
- Publication number
- RU2015142279A RU2015142279A RU2015142279A RU2015142279A RU2015142279A RU 2015142279 A RU2015142279 A RU 2015142279A RU 2015142279 A RU2015142279 A RU 2015142279A RU 2015142279 A RU2015142279 A RU 2015142279A RU 2015142279 A RU2015142279 A RU 2015142279A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- pharmaceutical composition
- composition
- particles
- hplc
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/92—Naphthofurans; Hydrogenated naphthofurans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Claims (19)
1. Композиция, содержащая очищенную форму соединения 1, его соль, сольват, гидрат или пролекарство,
где композиция обладает чистотой, большей или равной 95,0%, как определено посредством высокоэффективной жидкостной хроматографии (HPLC), ядерного магнитного резонанса (ЯМР) или и HPLC, и ЯМР,
и где композиция содержит 5% примесей или менее.
2. Композиция по п. 1, где композиция обладает чистотой, большей или равной 99%, как определено посредством HPLC, ЯМР или и HPLC, и ЯМР.
3. Композиция по п. 1, где композиция содержит 0,2% или менее каждой отдельной примеси.
4. Композиция по п. 1, где примеси содержат остаточный растворитель, выбранный из группы, состоящей из этилацетата (EtOAc), толуола, этанола, метанола, хлороформа и CH2Cl2/гексана.
5. Композиция по п. 1, где частицы содержат соединение в кристаллическом состоянии.
6. Композиция по п. 1, где фармацевтическая композиция содержит соединение, по меньшей мере, в двух различных полиморфных состояниях.
7. Фармацевтическая композиция по п. 1, где фармацевтическая композиция содержит соединение в аморфном состоянии.
8. Фармацевтическая композиция по п. 1, где фармацевтическая композиция содержит соединение в кристаллическом состоянии и соединение в аморфном состоянии.
9. Соединение, имеющее структуру, показанную ниже, его соль, сольват, гидрат или пролекарство,
где соединение находится в форме частицы и где частица имеет диаметр, меньший или равный приблизительно 20 микрометров.
10. Фармацевтическая композиция, содержащая совокупность частиц соединения по п. 9, где фракция суммарной совокупности частиц имеет диаметр в диапазоне от 0,2 мкм до 20 мкм.
11. Фармацевтическая композиция, содержащая совокупность частиц соединения по п. 9, где 50% суммарной совокупности частиц (D50) имеет диаметр приблизительно 2 мкм.
12. Фармацевтическая композиция по п. 10 или п. 11, где частицы содержат соединение в кристаллическом состоянии, аморфном состоянии или по меньшей мере двух различных полиморфных состояниях.
13. Фармацевтическая композиция по п. 10 или п. 11, где частицы содержат соединение в кристаллическом состоянии и соединение в аморфном состоянии.
14. Фармацевтическая композиция по п. 10 или п. 11, дополнительно содержащая фармацевтически приемлемый наполнитель.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31588610P | 2010-03-19 | 2010-03-19 | |
US31589010P | 2010-03-19 | 2010-03-19 | |
US61/315,890 | 2010-03-19 | ||
US61/315,886 | 2010-03-19 | ||
US32581410P | 2010-04-19 | 2010-04-19 | |
US61/325,814 | 2010-04-19 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2012144421/04A Division RU2571661C2 (ru) | 2010-03-19 | 2011-03-21 | Новые соединения и композиции для нацеливания на злокачественные стволовые клетки |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2015142279A true RU2015142279A (ru) | 2018-12-28 |
RU2015142279A3 RU2015142279A3 (ru) | 2019-02-26 |
Family
ID=50940329
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2015142279A RU2015142279A (ru) | 2010-03-19 | 2011-03-21 | Новые соединения и композиции для нацеливания на злокачественные стволовые клетки |
RU2016123004A RU2657750C1 (ru) | 2010-03-19 | 2011-03-21 | Новые способы направленного воздействия на раковые стволовые клетки |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2016123004A RU2657750C1 (ru) | 2010-03-19 | 2011-03-21 | Новые способы направленного воздействия на раковые стволовые клетки |
Country Status (9)
Country | Link |
---|---|
EP (2) | EP3295796A1 (ru) |
JP (11) | JP2014098050A (ru) |
CN (4) | CN107311969B (ru) |
CA (3) | CA2993363A1 (ru) |
DK (1) | DK3108750T3 (ru) |
ES (1) | ES2689928T3 (ru) |
NZ (2) | NZ712826A (ru) |
RU (2) | RU2015142279A (ru) |
SG (3) | SG10201502079VA (ru) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009036059A2 (en) | 2007-09-10 | 2009-03-19 | Boston Biomedical, Inc. | Novel stat3 pathway inhibitors and cancer stem cell inhibitors |
ES2689928T3 (es) * | 2010-03-19 | 2018-11-16 | 1Globe Biomedical Co., Ltd. | Compuestos y composiciones novedosas para direccionar hacia células madre del cáncer |
WO2011116399A1 (en) * | 2010-03-19 | 2011-09-22 | Boston Biomedical, Inc. | Novel methods for targeting cancer stem cells |
BR112015025347A2 (pt) | 2013-04-09 | 2017-07-18 | Boston Biomedical Inc | 2-acetil-nafto [2-3-b] furan-4,9-diona para uso no tratamento do câncer |
TW201717935A (zh) * | 2015-06-03 | 2017-06-01 | 波士頓生醫公司 | 用於治療癌症的組成物和方法 |
GB201515387D0 (en) * | 2015-08-28 | 2015-10-14 | Amazentis Sa | Compositions |
GB201515391D0 (en) * | 2015-08-28 | 2015-10-14 | Amazentis Sa | Compositions |
JP6751658B2 (ja) | 2016-11-15 | 2020-09-09 | クラリオン株式会社 | 音声認識装置、音声認識システム |
CA3045306A1 (en) | 2016-11-29 | 2018-06-07 | Boston Biomedical, Inc. | Naphthofuran derivatives, preparation, and methods of use thereof |
JP2020520923A (ja) | 2017-05-17 | 2020-07-16 | ボストン バイオメディカル, インコーポレイテッド | がんを処置するための方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61205257A (ja) * | 1985-03-08 | 1986-09-11 | Ishihara Sangyo Kaisha Ltd | ベンゾイルウレア系化合物、その製法及びそれを含有する抗ガン剤 |
EP0945131A1 (de) * | 1998-03-27 | 1999-09-29 | Boehringer Ingelheim Pharma KG | Perorale Wirkstoff-Suspension |
AU2736400A (en) * | 1999-01-27 | 2000-08-18 | University Of South Florida | Inhibition of stat3 signal transduction for human cancer therapy |
US20060142271A1 (en) * | 2002-09-17 | 2006-06-29 | Klaus Muller | Novel lapacho compounds and methods of use thereof |
AR042052A1 (es) * | 2002-11-15 | 2005-06-08 | Vertex Pharma | Diaminotriazoles utiles como inhibidores de proteinquinasas |
JP5288791B2 (ja) * | 2005-01-28 | 2013-09-11 | 武田薬品工業株式会社 | 難水溶性物質含有微細化組成物 |
JP2006290871A (ja) * | 2005-03-16 | 2006-10-26 | Taheebo Japan Kk | 抗癌性を示す化合物およびその中間体ならびにそれらの製造方法 |
TW200803854A (en) * | 2005-09-30 | 2008-01-16 | Smithkline Beecham Corp | Pharmaceutical compositions |
EP1860126A1 (en) * | 2006-05-26 | 2007-11-28 | INEOS Manufacturing Belgium NV | Polyolefin powder |
WO2009036059A2 (en) | 2007-09-10 | 2009-03-19 | Boston Biomedical, Inc. | Novel stat3 pathway inhibitors and cancer stem cell inhibitors |
CN104530061B (zh) * | 2008-07-08 | 2017-05-10 | 贝达药业股份有限公司 | 埃克替尼盐酸盐晶型、药物组合物和用途 |
ES2689928T3 (es) * | 2010-03-19 | 2018-11-16 | 1Globe Biomedical Co., Ltd. | Compuestos y composiciones novedosas para direccionar hacia células madre del cáncer |
NZ602328A (en) * | 2010-03-19 | 2014-11-28 | Boston Biomedical Inc | Novel compounds and compositions for targeting cancer stem cells |
WO2011116399A1 (en) * | 2010-03-19 | 2011-09-22 | Boston Biomedical, Inc. | Novel methods for targeting cancer stem cells |
-
2011
- 2011-03-21 ES ES16182813.2T patent/ES2689928T3/es active Active
- 2011-03-21 NZ NZ712826A patent/NZ712826A/en unknown
- 2011-03-21 SG SG10201502079VA patent/SG10201502079VA/en unknown
- 2011-03-21 CN CN201710613672.3A patent/CN107311969B/zh active Active
- 2011-03-21 RU RU2015142279A patent/RU2015142279A/ru not_active Application Discontinuation
- 2011-03-21 DK DK16182813.2T patent/DK3108750T3/en active
- 2011-03-21 EP EP17196754.0A patent/EP3295796A1/en active Pending
- 2011-03-21 CN CN201710665153.1A patent/CN107721958A/zh active Pending
- 2011-03-21 SG SG10201704745UA patent/SG10201704745UA/en unknown
- 2011-03-21 EP EP16182813.2A patent/EP3108750B1/en active Active
- 2011-03-21 CA CA2993363A patent/CA2993363A1/en not_active Abandoned
- 2011-03-21 SG SG10201706265PA patent/SG10201706265PA/en unknown
- 2011-03-21 RU RU2016123004A patent/RU2657750C1/ru active
- 2011-03-21 CN CN201710134235.3A patent/CN106860443A/zh active Pending
- 2011-03-21 CA CA2959951A patent/CA2959951A1/en not_active Abandoned
- 2011-03-21 CN CN201410101861.9A patent/CN104016951B/zh active Active
- 2011-03-21 NZ NZ701237A patent/NZ701237A/en unknown
- 2011-03-21 CA CA2959931A patent/CA2959931A1/en not_active Abandoned
-
2014
- 2014-03-03 JP JP2014040227A patent/JP2014098050A/ja not_active Withdrawn
- 2014-03-03 JP JP2014040226A patent/JP2014098049A/ja not_active Withdrawn
- 2014-03-03 JP JP2014040225A patent/JP5993390B2/ja not_active Expired - Fee Related
-
2015
- 2015-02-25 JP JP2015035285A patent/JP2015098489A/ja active Pending
- 2015-09-11 JP JP2015179115A patent/JP6246169B2/ja not_active Expired - Fee Related
-
2016
- 2016-09-30 JP JP2016194176A patent/JP2016222723A/ja not_active Withdrawn
-
2017
- 2017-10-13 JP JP2017199380A patent/JP2018002744A/ja not_active Withdrawn
-
2018
- 2018-04-20 JP JP2018081329A patent/JP2018115209A/ja not_active Withdrawn
-
2020
- 2020-01-31 JP JP2020014705A patent/JP2020063308A/ja not_active Withdrawn
- 2020-05-08 JP JP2020082479A patent/JP2020114888A/ja active Pending
-
2021
- 2021-12-06 JP JP2021197732A patent/JP2022020002A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2015142279A (ru) | Новые соединения и композиции для нацеливания на злокачественные стволовые клетки | |
RU2012144421A (ru) | Новые соединения и композиции для нацеливания на злокачественные стволовые клетки | |
DK2125705T3 (en) | Crystalline minocycline base and processes for their preparation | |
JP2013522325A5 (ru) | ||
KR102234597B1 (ko) | 피롤 유도체의 결정 및 그 제조 방법 | |
JP2016510323A5 (ru) | ||
IL258732A (en) | Salts and their benzene and polymorphs | |
RU2010152758A (ru) | Кристаллическая форма и тозилат соединения тетрациклина, кристаллическая форма указанного тозилата и ее полиморфная модификация, способ получения тозилата соединения тетрациклина, полиморфная модификация, полученная указанным способом, и фармацевтические композиции на основе вышеуказанных кристаллической формы и полиморфной модификации | |
US20110213150A1 (en) | Preparation of crystalline palonosetron hydrochloride | |
WO2009136995A3 (en) | 2, 6-diamino- pyrimidin- 5-yl-carboxamides as syk or jak kinases inhibitors | |
CN109311832A (zh) | 沃替西汀的帕莫酸盐及其晶型 | |
JP2014098050A5 (ru) | ||
EP2605767A1 (en) | Ship1 modulators and related methods | |
RU2018142490A (ru) | Кристаллические формы кризаборола в свободной форме и способ их получения и применения | |
ES2641299T3 (es) | (1R,4R)-6'-fluor-N,N-dimetil-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-1,1'-pirano[3,4,b]indol]-4-amina cristalina | |
EP2925753A1 (en) | Novel polymorphs of azilsartan medoxomil | |
JP5793134B2 (ja) | ペリレンテトラカルボン酸ジイミド化合物を含有してなる有機半導体材料、及び有機半導体素子 | |
CN103483333B (zh) | 盐酸戊乙奎醚外消旋体ⅰ的晶型及其制备方法 | |
CN103896763A (zh) | 一种2-(α-羟基戊基)苯甲酸钾多晶型及其制备方法、制剂与应用 | |
CN103319422A (zh) | 一种吉非替尼新晶型及其制备方法 | |
JP2013503823A5 (ru) | ||
RU2011143805A (ru) | Кристаллы гидробромата прасугреля | |
US20140378472A1 (en) | Amorphous vilazodone hydrochloride, a process for its preparation and pharmaceutical compositions thereof | |
JP2016172704A (ja) | デュロキセチン塩酸塩の製造方法、及び新規な結晶構造のデュロキセチン塩酸塩 | |
Washburn et al. | Synthesis and SAR of potent LXR agonists containing an indole pharmacophore |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20200114 |